Mayo Clinic work shows possible Lucentis side effect

ByConnor Hodde

At the Amercian Academy of Opthalmology 115th Annual Meeting, findings were presented from a retrospective study conducted after a Mayo Clinic opthalmologist noticed an increase in intraoccular pressure (IOP) in her patients using Genentech’ (Roche) Lucentis (ranibizumab), an FDA-approved drug for the treatment of age-related macular degeneration (AMD).

MARINA (Minimally Classic/OccultTrial of the Anti-Vascular Endothelial Growth Factor Antibody Ranibizumab in the Treatment of Neovascular Endothelial Age-Related Macular Degeneration) and ANCHOR (Anti-VEGF antibody for the treatment of predominantly classic Choroidal Neovascularization in Age-Related Macular Degeneration) evaluated drugs, including ranibizumab, for the treatment of AMD and other forms of MD.

http://www.bioopticsworld.com/news/2011/10/1530123521/mayo-clinic-work-shows-possible-lucentis-side-effect.html

Similar Posts

RetroSense Granted Orphan Drug Designation for Retinitis Pigmentosa

ByConnor Hodde

RetroSense Therapeutics, LLC, a privately-held biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the Company’s lead product RST-001 for the treatment of retinitis pigmentosa (RP). Retinitis pigmentosa is a genetic condition which leads to the progressive degeneration of rod and cone photoreceptors (cells found in…

American Health Assistance Foundation Announces Latest Grants to Advance Promising Vision Research

ByConnor Hodde

  The American Health Assistance Foundation (AHAF), a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world….

SDM Photocoagulation Superior to Intravitreal Injections of BCZ in the Treatment of CSC

ByConnor Hodde

A recent study was conducted to evaluate the treatment of central serous chorioretinopathy (CSC) with either subthreshold diode laser MicroPulse (SDM) or intravitreal bevacizumab (BCZ). The study was conducted over a period of 10 months and examined 52 eyes of 52 patients with (a) treatment with SDM at the active leakage site guided by fluorescein…

EyeCRO scientists contribute to study published in Nature

ByConnor Hodde

“Researchers have discovered a technique for directly reprogramming skin cells into light-sensing rod photoreceptors used for vision. The lab-made rods enabled blind mice to detect light after the cells were transplanted into the animals’ eyes. The work, funded by the National Eye Institute (NEI), published April 15 in Nature.” (Click here to read rest of article)

Activation of the molecular chaperone, sigma 1 receptor, preserves cone function in a murine model of inherited retinal degeneration.

ByConnor Hodde

Retinal degenerative diseases are major causes of untreatable blindness, and novel approaches to treatment are being sought actively. Here we explored the activation of a unique protein, sigma 1 receptor (Sig1R), in the treatment of PRC loss because of its multifaceted role in cellular survival.  We used Pde6βrd10 (rd10) mice, which harbor a mutation in…

Study found possible association between drug and age-related macular degeneration

ByConnor Hodde

Daily aspirin use among seniors may double their risk of developing a particularly advanced form of age-related macular degeneration, a debilitating eye disease, a large new European study suggests. The possible link involves the so-called “wet” type of age-related macular degeneration (AMD), a significant cause of blindness in seniors. http://www.nlm.nih.gov/medlineplus/news/fullstory_120483.html